在重症监护病房接受利妥昔单抗治疗的严重肺炎患者的预后因素。
Prognostic factors of severe pneumonia in patients treated with rituximab in the intensive care unit.
作者信息
Yao Lili, Huang Yu, Xu Andi
机构信息
Department of Nephrology, Lishui Central Hospital; Lishui Hospital of Zhejiang University; the Fifth Affiliated Hospital of Wenzhou University, Lishui, China.
Department of Infectious Diseases, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
出版信息
J Int Med Res. 2022 Mar;50(3):3000605211063281. doi: 10.1177/03000605211063281.
OBJECTIVE
The aim of this study was to describe the clinical characteristics and prognostic factors of patients treated with rituximab (RTX) who developed severe pneumonia in the intensive care unit (ICU).
METHODS
We systematically reviewed the medical records of 40 patients who received RTX and developed severe pneumonia in the ICU at our hospital from January 2009 to January 2019 to evaluate the underlying conditions, clinical course, and possible prognostic factors.
RESULTS
Most patients had underlying hematologic malignancies (n = 21, 52.5%), followed by rheumatologic diseases (n = 17, 42.5%). The most frequent causative pathogens were fungi (n = 11, 27.5%), followed by bacteria (n = 9, 22.5%) and pneumonia (n = 8, 20%). Thirty patients (75%) died, and the other 10 patients (25%) survived. Compared with survivors, patients who died were significantly older (60.6 ± 10.6 vs 44.4 ± 18.3 years) and had chronic lung disease (40% vs 0%).
CONCLUSION
Older age and chronic lung disease were significantly associated with mortality in patients treated with RTX.
目的
本研究旨在描述在重症监护病房（ICU）接受利妥昔单抗（RTX）治疗并发生重症肺炎的患者的临床特征和预后因素。
方法
我们系统回顾了2009年1月至2019年1月在我院ICU接受RTX治疗并发生重症肺炎的40例患者的病历，以评估其基础疾病、临床病程及可能的预后因素。
结果
大多数患者患有血液系统恶性肿瘤（n = 21，52.5%），其次是风湿性疾病（n = 17，42.5%）。最常见的致病病原体是真菌（n = 11，27.5%），其次是细菌（n = 9，22.5%）和病毒（n = 8，20%）。30例患者（75%）死亡，其余10例患者（25%）存活。与幸存者相比，死亡患者年龄显著更大（60.6±10.6岁 vs 44.4±18.3岁）且患有慢性肺病（40% vs 0%）。
结论
年龄较大和患有慢性肺病与接受RTX治疗的患者的死亡率显著相关。
Zotero 插件